Program
TLR7 Agonist JNJ-64794964
Also written as “TQ-A3334 tablets”, “TQ-A3334” and “TQA3334 Tablet”.
In Sino Biopharmaceutical’s pipeline, TLR-7激动剂
. Its studies are mostly in Hepatitis B, Chronic · Hepatitis B · Carcinoma, Non-Small-Cell Lung, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 51 open or running | phase 2since Nov 26, 2019 | Nov 26, 2019 | none ahead |
| Johnson & Johnson | 10 open or running | phase 1since Aug 15, 2017 | Aug 15, 2017 | none ahead |
- Named in Sino Biopharmaceutical’s own pipeline as
TQ-A3334
, phase 2, as of Nov 16, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 15, 2017First study: phase 1 study in Hepatitis BNew to Johnson & JohnsonJohnson & Johnson · NCT03285620 · 42 enrolled · New Zealand
- Nov 26, 2019Sino Biopharmaceutical’s first study: phase 2 study in Hepatitis B, ChronicNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT04180150 · 12 enrolled · China
- Feb 16, 2020Phase 2 study in Carcinoma, Non-Small-Cell LungSino Biopharmaceutical · NCT04273815 · 40 enrolled · China
- Nov 30, 2023Phase 1 study in Hepatitis BSino Biopharmaceutical · NCT06160895 · 40 enrolled · China
- Jul 11, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungSino Biopharmaceutical · NCT06507891 · 30 enrolled · China
- Nov 20, 2024Phase 2 study in Hepatitis B, ChronicSino Biopharmaceutical · NCT06706310 · 116 enrolled · China
TargetBeta
“TLR-7激动剂”the company's pipeline, read by Claude · source
Other programs on TLR7
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| resiquimodrule | Staidson (Beijing) Biopharmaceuticals | phase 3 | 14 |
| enpatoranrule | Merck KGaA, Darmstadt, Germany | phase 3 | 12 |
| afimetoranrule | Bristol-Myers Squibb | phase 3 | 12 |
| Cholesteryl Pullulan Nanoparticle-formulated TLR7/8 Agonist UI-102rule | united-immunity-co-ltd | phase 2 | 1 |
| PRTX007rule | primmune-therapeutics-inc | phase 2 | 1 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06706310Hepatitis B, Chronic · China | 2 | Active, not recruiting | Sino Biopharmaceutical | Dec 7, 2025 | 116 |
| NCT06507891Carcinoma, Non-Small-Cell Lung · China | 2 | Terminated | Sino Biopharmaceutical | Aug 25, 2023 | 30 |
| NCT06160895Hepatitis B · China | 1 | Completed | Sino Biopharmaceutical | Jun 24, 2024 | 40 |
| NCT04273815Carcinoma, Non-Small-Cell Lung · China | 2 | UNKNOWN | Sino Biopharmaceutical | Jan 31, 2021 | 40 |
| NCT04180150Hepatitis B, Chronic · China | 2 | UNKNOWN | Sino Biopharmaceutical | Sep 30, 2020 | 12 |
| NCT03285620Hepatitis B · New Zealand | 1 | Completed | Johnson & Johnson | Nov 14, 2018 | 42 |
How it is read
Names in the registry
- “TQ-A3334 tablets”, 2 entries
- “TQ-A3334”, 2 entries
- “TQA3334 Tablet”, 1 entry
- “AL-034”, 1 entry
- “TQ-A3334 tablets + Anlotinib capsules”, 1 entry
Conditions, from the studies’ own filings
- Hepatitis B, Chronic, 2 studies
- Hepatitis B, 2 studies
- Carcinoma, Non-Small-Cell Lung, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.